2-(5-piperidin-4-yl-2H-[1,2,4]triazol-3-yl)-4-trifluoromethyl-pyridine hydrochloride | 1240108-73-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(5-piperidin-4-yl-2H-[1,2,4]triazol-3-yl)-4-trifluoromethyl-pyridine hydrochloride
• 英文别名: 2-(5-piperidin-4-yl-1H-1,2,4-triazol-3-yl)-4-(trifluoromethyl)pyridine;hydrochloride
• CAS: 1240108-73-9
• 化学式: C₁₃H₁₄F₃N₅*ClH
• 分子量: 333.744
• InChiKey: XSTJEJCZZJLXCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] FUSED PYRIMIDINES AS AKT INHIBITORS<br/>[FR] PYRIMIDINES CONDENSÉES EN TANT QU'INHIBITEURS D'AKT
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010091824A1

  公开（公告）日：2010-08-19

  The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  本发明涉及式(I)的化合物，其N-氧化物或互变异构体或立体异构体，或其盐，其中环B和与其融合的咪唑，R4、R6、R7、R10、m和n的含义如描述和权利要求中所给出，这些化合物是Pi3K/Akt途径的有效抑制剂，其生产过程及其作为药物的用途。
• FUSED PYRIMIDINES
  申请人：Beckers Barbara

  公开号：US20130317002A1

  公开（公告）日：2013-11-28

  Compounds of formula (I) or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6, R7, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  式(I)的化合物或其N-氧化物、盐、互变异构体或立体异构体的盐或N-氧化物、互变异构体或立体异构体，其中环B和与其融合的嘧啶基团R4、R5、R6、R7、m和n的含义如说明书和权利要求所述，它们是有效的Pi3K/Akt途径抑制剂，其制备方法及其作为药物的用途。
• FUSED PYRIMIDINES AS AKT INHIBITORS
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2396331B1

  公开（公告）日：2013-10-16
• US8957064B2
  申请人：——

  公开号：US8957064B2

  公开（公告）日：2015-02-17
• [EN] FUSED PYRIMIDINES<br/>[FR] PYRIMIDINES CONDENSÉES
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010091808A1

  公开（公告）日：2010-08-19

  Compounds of formula (I), or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6, R7, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.